Orphanet Journal of Rare Diseases | Phenotypic and Genotypic Analysis of ABCC6 Deficiency in Childhood

Recommend:

This study presents the first systematic analysis of clinical phenotypes and genetic variants of ABCC6 deficiency in the pediatric population, revealing significant phenotypic heterogeneity and providing critical insights for clinical diagnosis and genetic screening.

 

Literature Overview
This article, 'Pediatric ABCC6 deficiency: a genotypic and phenotypic analysis', published in Orphanet Journal of Rare Diseases, reviews and summarizes the genotypic and phenotypic manifestations of ABCC6 deficiency in children. The study analyzed 95 children with ABCC6 variants, finding that 55.8% were diagnosed with GACI2 and 44.2% with PXE. It was also observed that infants primarily presented with vascular and soft tissue calcifications, whereas older children predominantly exhibited cutaneous and ocular symptoms. Notably, significant variability in clinical presentation was found among individuals with the same ABCC6 variant, suggesting that phenotypes may be influenced by other genetic or environmental factors. The study emphasizes that ABCC6 deficiency may be underdiagnosed in childhood and recommends establishing standardized evaluation and genetic diagnostic guidelines to improve early recognition and multidisciplinary management.

Background Knowledge
The ABCC6 gene encodes a transmembrane transporter primarily expressed in hepatocytes and proximal tubule cells of the kidney. Deficiency of this gene leads to reduced extracellular ATP levels, thereby decreasing PPi (inorganic pyrophosphate) production, which results in ectopic calcifications and pathological vascular changes. ABCC6 deficiency is associated with two major phenotypes: GACI2 (Generalized Arterial Calcification of Infantile, 2nd type) and PXE (Pseudoxanthoma Elasticum), with the former presenting in infancy and the latter typically in adolescence or adulthood. Both phenotypes involve ectopic calcifications in blood vessels, skin, eyes, and the nervous system, but differ in age of onset and organ involvement. Although more than 300 ABCC6 variants have been identified, only 35% are clearly pathogenic. Most current data come from case reports, with a lack of systematic phenotypic analysis. This study fills the gap in pediatric ABCC6 deficiency phenotypic spectrum, revealing no clear genotype-phenotype correlation and suggesting a comprehensive assessment integrating multi-omics and environmental factors. Importantly, some individuals with only a single allelic variant also exhibited significant clinical symptoms, indicating potential recessive variants or modifier effects. These findings are crucial for genetic counseling and early screening.

 

Assesses the pathogenicity of gene variants and provides reference for variant function analysis.

Learn More

 

Research Methods and Experiments
The study collected 95 pediatric ABCC6 variant carriers through literature review and two natural history studies (NCT03478839 and NCT03758534), of which 76 were from published literature and 19 from clinical studies. The inclusion criteria were patients reported with clinical phenotypes between the ages of 0 and 18. A total of 133 ABCC6 variants were identified, with 57.1% classified as pathogenic, 26.3% as likely pathogenic, and 10.5% as variants of uncertain significance. After data integration, the study analyzed genotype-phenotype correlations, age-related distribution of systemic complications, and variant types.

Key Findings and Insights

• ABCC6 deficiency in childhood can manifest as either GACI2 or PXE, but with significant phenotypic overlap, suggesting caution in clinical classification.
• 55.8% of cases were diagnosed as GACI2 and 44.2% as PXE, though many individuals exhibited features of both diseases.
• Infants mainly presented with vascular calcifications and cardiovascular complications, while cutaneous and ocular symptoms typically appeared after age 2.
• Significant phenotypic variability was observed among individuals with the same ABCC6 variant, indicating the influence of other modifier genes or environmental factors.
• 27.4% of patients carried only one ABCC6 variant but exhibited similar clinical features as those with biallelic variants, suggesting the presence of undetected recessive or deep intronic variants.
• Some GACI2 patients showed rickets-like skeletal changes, likely due to bisphosphonate therapy rather than the ABCC6 deficiency itself.
• The study highlights the potential underdiagnosis of ABCC6 deficiency in childhood and recommends standardized screening and management protocols.

Research Implications and Future Directions
This study provides systematic data for the diagnosis of ABCC6 deficiency in childhood and reveals its clinical manifestations across different age groups. Future work should focus on establishing unified evaluation criteria and integrating multi-omics approaches to understand the mechanisms behind phenotypic heterogeneity. The study recommends ABCC6 gene screening for all infants with severe vascular calcification and including ABCC6 as a candidate gene in suspected adolescent cases. Further exploration of the interaction between ABCC6 and other genes (e.g., ENPP1) and their impact on phenotypic modification is also needed.

 

Enter a gene to view its associated signaling pathways and known upstream/downstream molecules.

Learn More

 

Conclusion
ABCC6 deficiency can lead to widespread calcification-related disorders from infancy to adolescence, including the two major phenotypes GACI2 and PXE. This study provides the first systematic analysis of the genotypic and phenotypic distribution of ABCC6 deficiency in children, revealing highly heterogeneous clinical manifestations without a clear genotype-phenotype correlation. Many patients develop cardiovascular, neurological, and ocular complications at an early age, underscoring the need for clinicians to recognize the diverse presentation of this disease in childhood. The study recommends the establishment of standardized evaluation protocols, including genetic testing, imaging-based calcification screening, and multidisciplinary management, to improve early diagnosis and intervention. Additionally, it notes that some individuals with only a single ABCC6 variant exhibit typical clinical features, suggesting the presence of recessive variants or other modifying factors. Future studies should incorporate comprehensive genomic analyses to explore the molecular mechanisms of ABCC6 deficiency and its potential associations with other diseases, providing a more precise basis for clinical genetic counseling and therapeutic strategies.

 

Marta Bertamino, David J Goldberg, M Zulf Mughal, Carlos R Ferreira, and Shira G Ziegler. Pediatric ABCC6 deficiency: a genotypic and phenotypic analysis. Orphanet Journal of Rare Diseases.